You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Integrated, self-actuated, blood collection and biomarker purification device

    SBC: Tasso, Inc            Topic: SB122003

    Blood-based point-of-care (POC) diagnostics or remote diagnostics that require specialized equipment only available in centralized, commercial laboratories are currently limited by major logistical and technical barriers. Blood collection can be a traumatic, inconvenient, and inconsistent process that is based on decades-old technologies, such as the lancet-puncture, that are not amenable to new P ...

    SBIR Phase II 2014 Department of DefenseDefense Advanced Research Projects Agency
  2. CLIA-waived Point of Care Test of Infection by Cocci, Blasto, and Histo

    SBC: LUCIGEN CORPORATION            Topic: N/A

    Human cytomegalovirus (CMV) infection causes more cases of congenital disease than 29 currently screened conditions in the US combined & several newborn screening disorders in EU countries. Congenital CMV infection rate is 0.7% in developed countries with 18% of infected newborns developing permanent hearing & vision loss, or intellectual disability (5,000 in the US each year). Ninety percent of ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Antifungal Compound Discovery from Metagenomes

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel system for sensitive detection of botulinum neurotoxins

    SBC: ALPHA UNIVERSE LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The existence of terrorist organizations around the world, along with their ability to recruit expertise from physicians and scientists, poses an increasing threat of bioterrorist attack to society. In order to reduce the consequences of such an attack or even prevent it, new systems for detection of biothreat agents are necessary. Currently existing express ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. BAC Sudoku Sequencing Paradigm to Accelerate Metagenomic Natural Product Chemistr

    SBC: LUCIGEN CORPORATION            Topic: NCCIH

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against microbial pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antimicrobial compounds with potentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Increased bioavailability of polyphenols through bacterial metabolism

    SBC: AGRO BIOSCIENCES, INC.            Topic: NCCIH

    DESCRIPTION (provided by applicant): Numerous preclinical studies have demonstrated multiple health benefits including anti- inflammatory, antioxidant, and chemopreventive effects of dietary polyphenols. These compounds are abundant in plants and have added to the health benefits of many fruits, such as raspberries, pomegranates, and strawberries. As aging population in the U.S. and other develope ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment

    SBC: CENTROSE LLC            Topic: NCI

    Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cases and 13,680 deaths will be attributed to renal cancerin the United States. Renal cancer is the most common malignancy of the adult kidney and accounts for 2-3% of all adult malignancies. Of these, 3 ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Long acting injected liposomal buprenorphine for chronic pain/addiction in people

    SBC: Plumb Pharmaceuticals LLC            Topic: NIDA

    DESCRIPTION: In this proposal, Comfort Care for Animals LLC (CCA) (Madison, WI) will create slow-release (minimum 10-12 days in this Phase, with an ultimate goal of 28 days) injectable liposomal buprenorphine formulation to treat moderate to severe post-surgical or chronic pain in people and animals and to use as a treatment for opioid addiction in people. This innovative new drug-delivery system ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Cell-based Real Time Platform for GPCR Drug Discovery

    SBC: LUCIGEN CORPORATION            Topic: NIGMS

    Abstract High throughput screening assays for GPCR drug discovery are hampered by the complex instrumentation associated with current technologies, and the high risk of false-positives and off- target effects. The majority of currently available GPCR drugscreening assays are end-point assays that rely on secondary reporters of GPCR signaling events after signaling has occurred. These assays are fu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government